Cardiovascular and hepatic disease associations by magnetic resonance imaging: A retrospective cohort study

Alan C. Kwan, Nancy Sun, Matthew Driver, Patrick Botting, Jesse Navarrette, David Ouyang, Shehnaz K. Hussain, Mazen Noureddin, Debiao Li, Joseph E. Ebinger, Daniel S. Berman, Susan ChengFrontiers in Cardiovascular Medicine 2022 · DOI

Abstract

Elevated FIB-4 was associated with cardiac functional and vascular abnormalities even after adjustment for shared risk factors in a cohort of patients with clinically referred CMR. These CMR findings indicate that cardiovascular abnormalities exist in the presence of subclinical hepatic fibrosis, irrespective of shared risk factors, underscoring the need for further studies of the heart-liver axis.

Introduction

The "heart-liver axis" describes the complex interplay between hepatic health and cardiovascular function. While it is well-established that patients with liver diseases like Non-Alcoholic Fatty Liver Disease (NAFLD) face higher cardiovascular risks, it remains unclear if liver dysfunction actively drives heart disease or if they simply share metabolic risk factors like obesity and hypertension. This retrospective cohort study addresses this gap by using Cardiac Magnetic Resonance (CMR)—the gold standard for heart assessment—to identify subclinical changes associated with liver fibrosis.

Methods

The study analyzed 1,668 patients from the Cedars-Sinai Health System (2010–2021) who underwent clinical CMR and had concurrent laboratory data. Hepatic fibrosis risk was estimated using the FIB-4 score (calculated from age, platelet count, and AST/ALT levels), categorized into low (<1.3), moderate (1.3–3.25), and high (>3.25) risk groups. CMR findings were categorized into four domains: structure, function, vascular, and composition. Poisson regression was used to calculate Prevalence Ratios (PR), adjusting for age, sex, race, BMI, and traditional cardiovascular risk factors.

Key Results

The study found a significant association between liver fibrosis markers and specific cardiac and vascular changes. Notably, the prevalence of any cardiac abnormality increased linearly with the FIB-4 category.

Multivariable adjusted prevalence ratios for cardiac functional and vascular abnormalities across hepatic fibrosis (FIB-4) categories.
  • Functional Abnormalities: Patients in the high FIB-4 group were 41% more likely to exhibit functional cardiac abnormalities (PR 1.41, 95% CI 1.21–1.65) compared to the low-risk group, primarily driven by abnormal left ventricular output.
  • Vascular Abnormalities: Moderate FIB-4 scores were associated with a 22% increased likelihood of vascular abnormalities (PR 1.22, 95% CI 1.01–1.47), specifically driven by increased ascending aortic size.
  • Independence from Metabolic Factors: These associations persisted after full multivariable adjustment, including BMI, suggesting a pathological pathway distinct from shared metabolic risks.
  • Structural and Compositional Findings: Interestingly, no significant differences were found in heart structure (e.g., wall thickness) or composition (e.g., scarring) after adjustment, suggesting that functional and vascular changes may precede structural remodeling.

Discussion and Limitations

These findings suggest that subclinical liver disease may trigger a "hyperdynamic" state, characterized by increased cardiac output and vascular remodeling. However, as a retrospective, cross-sectional study, causality cannot be definitively established. The cohort also consisted of patients already referred for CMR, which may introduce referral bias. Future longitudinal studies using more direct measures of liver fibrosis, such as Liver MRI, are needed to determine if improving liver health can mitigate these cardiovascular changes.

Summary updated

Abstract

Elevated FIB-4 was associated with cardiac functional and vascular abnormalities even after adjustment for shared risk factors in a cohort of patients with clinically referred CMR. These CMR findings indicate that cardiovascular abnormalities exist in the presence of subclinical hepatic fibrosis, irrespective of shared risk factors, underscoring the need for further studies of the heart-liver axis.
BibTeX
@inproceedings{kwan2022cardiovascular,
  author = {Alan C. Kwan and Nancy Sun and Matthew Driver and Patrick Botting and Jesse Navarrette and David Ouyang and Shehnaz K. Hussain and Mazen Noureddin and Debiao Li and Joseph E. Ebinger and Daniel S. Berman and Susan Cheng},
  title = {{Cardiovascular and hepatic disease associations by magnetic resonance imaging: A retrospective cohort study}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2022},
  doi = {10.3389/fcvm.2022.1009474},
}
Figure